文献速递血栓与止血

解读腺相关病毒肝脏靶向基因治疗的难题:聚焦血友病

Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia.
PubMed 文献 · J Thromb Haemost · 2023-12-14

腺相关病毒基因治疗单基因疾病研究超过25年,但获监管批准的疗法极少,多数因毒性或疗效不足止步于1/2期。肝脏因多数血清型对肝细胞高度嗜性及肝窦几何结构利于病毒与肝细胞表面接触而成为天然靶标。血友病等隐性单基因病因缺陷蛋白多在肝脏合成并分泌入血、易于检测且多无需精确调控而成为有希望的靶标,但治疗窗常不存在,导致毒性过多和疗效不足;血友病首次获批因子IX和因子VIII基因治疗是在首个人类基因治疗研究25年后。

要点

  • 腺相关病毒基因治疗单基因病研究超过25年,获监管批准的疗法极少。
  • 多数疗法因毒性、疗效不足或两者兼有而未进展至1/2期之后。
  • 血友病因子IX和因子VIII基因治疗在首个人类基因治疗研究25年后首次获监管批准。

核心结论

  • 尽管成功的基因转移可能产生足够的转基因蛋白以改善疾病,但关于耐久性、可预测性、可靠性和反应变异性的许多新问题尚未得到解答。
  • 解释这些异质性反应的潜在生物学以及宿主与病毒之间的相互作用是本文综述的主题。

研究设计与样本

  • 综述,聚焦腺相关病毒肝脏靶向基因治疗血友病的难题。

主要发现

  • 腺相关病毒基因治疗单基因疾病研究超过25年,但获监管批准的疗法极少。
  • 多数疗法因毒性、疗效不足或两者兼有而未进展至1/2期之后。
  • 血友病因子IX和因子VIII基因治疗在首个人类基因治疗研究25年后首次获监管批准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 许多关于耐久性、可预测性、可靠性和反应变异性的新问题尚未得到解答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adeno-associated virus gene therapy has been the subject of intensive investigation for monogenic disease gene addition therapy for more than 25 years, yet few therapies have been approved by regulatory agencies. Most have not progressed beyond phase 1/2 due to toxicity, lack of efficacy, or both. The liver is a natural target for adeno-associated virus since most serotypes have a high degree of tropism for hepatocytes due to cell surface receptors for the virus and the unique liver sinusoidal geometry facilitating high volumes of blood contact with hepatocyte cell surfaces. Recessive monogenic diseases such as hemophilia represent promising targets since the defective proteins are often synthesized in the liver and secreted into the circulation, making them easy to measure, and many do not require precise regulation. Yet, despite initiation of many disease-specific clinical trials, therapeutic windows are often nonexistent, resulting in excess toxicity and insufficient efficacy. Iterative progress built on these attempts is best illustrated by hemophilia, with the first regulatory approvals for factor IX and factor VIII gene therapies eventually achieved 25 years after the first gene therapy studies in humans. Although successful gene transfer may result in the production of sufficient transgenic protein to modify the disease, many emerging questions on durability, predictability, reliability, and variability of response have not been answered. The underlying biology accounting for these heterogeneous responses and the interplay between host and virus is the subject of intense investigation and the subject of this review.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Pierce GF, Fong S, Long BR, et al. Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia. J Thromb Haemost. 2023. PMID: 38103734. doi:10.1016/j.jtha.2023.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。